ASCO 2024: SURE1 - Neoadjuvant Sacituzumab Govitecan in Urothelial Carcinoma

By The Uromigos - Last Updated: July 10, 2024

Dr. Andrea Necchi describes the efficacy and toxicity of neoadjuvant sacituzumab govitecan in urothelial carcinoma from the new SURE1 trial.

Post Tags:Uromigos-ASCO

Related Podcasts

Episode 398: Reflections on the Felix Feng Symposium at ASCO GU

Episode 397: APCCC Diagnostics Conference Recap

Uromigos-Prostate Cancer

Episode 394: APCCC (Advanced Prostate Cancer Consensus Conference) Diagnostics 2025

Uromigos-Prostate Cancer

Episode 393: ASCO GU 2025 Review Podcast

Episode 392: ASCO GU 2025 - HIF Inhibition With Casdatifan in Refractory RCC

Uromigos-Kidney Cancer